Correction to “In Vitro and in Vivo Evaluation of Osteoporosis

Addition and Correction Cite This: Mol. Pharmaceutics XXXX, XXX, XXX−XXX

pubs.acs.org/molecularpharmaceutics

Correction to “In Vitro and in Vivo Evaluation of Osteoporosis Therapeutic Peptide PTH 1−34 Loaded PEGylated Chitosan Nanoparticles” Deepa Narayanan, A. Anitha, R. Jayakumar,* and K. P. Chennazhi* Amrita Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham University, Kochi 682041, India

Mol. Pharmaceutics; 2013, 10 (11), pp 4159−4167. DOI: 10.1021/mp400184v

Mol. Pharmaceutics Downloaded from pubs.acs.org by 31.40.211.143 on 02/26/19. For personal use only.

I

n the original article, the image of Figure 8B was inadvertently repeated as Figure 8D2. Both images were from the control PTH 1−34-treated group. Therefore, the original D2 panel has been removed from Figure 8, and now, only three images appear as D1−D3 (not D1−D4). The corrected figure and the corresponding legend are presented here.

Figure 8. Light microscope image primary osteoblast cells after 7 days: (A) grown in osteoblast specific medium; (B) after treating with PTH 1−34 showing increased cell number; (C) after treating with CS NPs; (D1−D3) after treating with PEG-CS-PTH NPs showing high cell number; osteoblast specific concentric arrangement of cells is indicated by the arrows.

© XXXX American Chemical Society

A

DOI: 10.1021/acs.molpharmaceut.9b00171 Mol. Pharmaceutics XXXX, XXX, XXX−XXX